Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Osilodrostat - ISTURISA
Product / population
Adult oral osilodrostat; selected renal and monitoring information, not a complete titration protocol.
Renal method
Qualitative renal impairment; urinary free cortisol is a monitoring measure, not a kidney-function estimator.
Source revision
Prescribing information revised 11/2025.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ISTURISA: no renal dose adjustment does not remove the cortisol-assay caveat
Both selected sources pair no renal dose adjustment with caution interpreting urinary free cortisol in moderate or severe impairment.
What to reconcile: Retain the monitoring limitation during endocrine assessment and titration.
DailyMed / Recordati Rare Diseases Inc. · Adult oral osilodrostat; selected renal and monitoring information, not a complete titration protocol.
Renal method: Qualitative renal impairment; urinary free cortisol is a monitoring measure, not a kidney-function estimator. Source date: Prescribing information revised 11/2025. Retrieved: 2026-09-08
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is required. However, reduced urinary free cortisol excretion in moderate or severe renal impairment makes urinary cortisol results harder to interpret. Preserve this assay caveat during dose titration; a no-adjustment statement does not mean monitoring is unaffected.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.